EU agency accepts Sandoz application for pegfilgrastim biosimilar
February 11, 2016 at 01:30 AM EST
ZURICH, Feb 11 (Reuters) - The European Medicines Agency (EMA) has accepted an application to review Sandoz's biosimilar to Amgen's EU-licensed Neulasta (pegfilgrastim), a recombinant human granulocyte colony-stimulating factor, Sandoz parent Novartis said on Thursday.
